---
document_datetime: 2025-02-03 11:47:53
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fortacin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: fortacin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.3424877
conversion_datetime: 2025-12-19 02:15:43.63435
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Fortacin

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0040               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                      | 31/01/2025                          |                                             | Labelling and PL                 |           |
| IA/0039              | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 18/11/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                       |                                                                                                                                                                                                                                                                        |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0038              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 20/07/2023 | 15/09/2023 | SmPC, Annex II and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Fortacin in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0037           | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                            | 21/02/2023 | n/a        |                       |                                                                                                                                                                                                                                                                        |
| PSUSA/10110 /202205 | Periodic Safety Update EU Single assessment - lidocaine / prilocaine (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/01/2023 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| II/0035/G           | This was an application for a group of variations. B.IV.1.c - Change of a measuring or administration device - Addition or replacement of a device which is an integrated part of the primary packaging B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.b.1.e - Replacement or addition of a | 15/09/2022 | 15/09/2023 | Annex II and PL       | The manufacturing site Genetic S.p.A., Via Canfora, 64, 84084 Fisciano (SA), Italy is added in Annex IIA as a manufacturer responsible for batch release.                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           | site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process   |            |            |                 | manufacturing   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------|
| IA/0034/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                | 13/04/2022 | n/a        |                 |                 |
| IA/0033   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 27/07/2021 | 08/07/2022 | Annex II and PL |                 |
| IA/0032   | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 25/09/2020 | n/a        |                 |                 |

<div style=\"page-break-after: always\"></div>

| II/0030             | Change in the legal status of Fortacin from 'medicinal product subject to medical prescription' to 'medicinal product not subject to medical prescription'. As a consequence, sections 4.4, 4.8, 4.9 of the SmPC are updated. The package leaflet and labelling are updated accordingly. Furthermore, the product information is being brought in line with the latest QRD template (version 10.1). The RMP is updated to version 4.0. C.I.5.b - Change in the legal status of a medicinal product for centrally authorised products - All other legal status changes   | 23/07/2020   | 27/08/2020   | SmPC, Annex II, Labelling and PL   | Please refer to Scientific Discussion 'Fortacin-H-C-2693-II- 0030'. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0031             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                              | 16/12/2019   | n/a          |                                    |                                                                                                                                                     |
| PSUSA/10110 /201905 | Periodic Safety Update EU Single assessment - lidocaine / prilocaine (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 28/11/2019   | n/a          |                                    | PRAC Recommendation - maintenance                                                                                                                   |
| IAIN/0029           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                  | 02/10/2019   | n/a          |                                    |                                                                                                                                                     |
| IAIN/0027/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11/03/2019   | 09/03/2020   | Annex II and PL                    |                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                     | manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10110 /201805 | Periodic Safety Update EU Single assessment - lidocaine / prilocaine (centrally authorised product only)                                                                                                                                                                                          | 29/11/2018 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0026             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                        | 06/11/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0023              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                           | 26/07/2018 | 17/09/2018 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Fortacin in the approved indication remains favourable, but recommended that one additional five-year renewal be required based on the following pharmacovigilance grounds: Limited safety information is available because of limited exposure, due to recent marketing and the limited marketing of the medicinal product. |
| IA/0025             | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                                                                    | 29/08/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0022             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                     | 15/02/2018 | 17/09/2018 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IB/0020             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                            | 02/02/2018   | n/a        |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IA/0021/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished                 | 24/01/2018   | n/a        |                        |                                   |
| PSUSA/10110 /201705 | Periodic Safety Update EU Single assessment - lidocaine / prilocaine (centrally authorised product only)                                                                                                                                                                                                 | 30/11/2017   | n/a        |                        | PRAC Recommendation - maintenance |
| T/0019              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                      | 11/10/2017   | 30/10/2017 | SmPC, Labelling and PL |                                   |
| IB/0017/G           | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 27/06/2017   | n/a        |                        |                                   |
| PSUSA/10110         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                            | 09/06/2017   | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| /201611             | lidocaine / prilocaine (centrally authorised product only)                                                                                                                                                                                             |            |            |                                  |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| II/0015             | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                    | 23/03/2017 | n/a        |                                  |                                   |
| N/0014              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                       | 18/01/2017 | 17/03/2017 | Labelling                        |                                   |
| PSUSA/10110 /201605 | Periodic Safety Update EU Single assessment - lidocaine / prilocaine (centrally authorised product only)                                                                                                                                               | 01/12/2016 | n/a        |                                  | PRAC Recommendation - maintenance |
| N/0013              | Update of the package leaflet to include the list of local representatives. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                           | 08/08/2016 | 17/03/2017 | PL                               |                                   |
| PSUSA/10110 /201511 | Periodic Safety Update EU Single assessment - lidocaine / prilocaine (centrally authorised product only)                                                                                                                                               | 09/06/2016 | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0011/G           | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site | 17/05/2016 | 17/03/2017 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|             | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.5.d - Change in pack size of the finished product - Change in the fill weight/fill volume of nonparenteral multi-dose (or single-dose, partial   |            |            |                 |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IAIN/0010/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the                                                                                                                                                                                                                                                                                                                                                        | 19/04/2016 | 17/03/2017 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

|                     | relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)   |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10110 /201505 | Periodic Safety Update EU Single assessment - lidocaine / prilocaine (centrally authorised product only)                                                                                                                                                                                      | 03/12/2015 | n/a | PRAC Recommendation - maintenance |
| PSUSA/10110 /201411 | Periodic Safety Update EU Single assessment - lidocaine / prilocaine (centrally authorised product only)                                                                                                                                                                                      | 11/06/2015 | n/a | PRAC Recommendation - maintenance |
| IA/0007             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                   | 27/03/2015 | n/a |                                   |
| IA/0006             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                   | 27/03/2015 | n/a |                                   |
| IB/0005             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                | 20/03/2015 | n/a |                                   |
| PSUV/0001           | Periodic Safety Update                                                                                                                                                                                                                                                                        | 04/12/2014 | n/a | PRAC Recommendation - maintenance |
| IAIN/0003           | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV                                                                                                                                                                                               | 28/11/2014 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|             | (including contact details) and/or changes in the location                                                                                                                                                                                                                                                                          |            |            |                        | PSMF             |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------|
| IAIN/0002/G | This was an application for a group of variations. A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from (replacement or addition) | 26/09/2014 | 15/10/2015 | SmPC, Labelling and PL | new manufacturer |